New Haven Drug Maker Starting Clinical Trial of Alzheimer's Treatment
A New Haven drugmaker and Hamden research center have been
paired in a new, late-stage clinical trial to slow or stop the symptoms of
Alzheimer’s disease.
Biohaven Pharmaceuticals announced it enrolled its first
patient in August, and is still seeking more participants for the study, which
is being coordinated by the Alzheimer’s Disease Cooperative Study at the
University of California, San Diego.
The GAP Center — the
Geriatric and Adult Psychiatry Clinical Care and Research Center — in Hamden
will be the first of 32 sites around the country to participate in the trial of
Biohaven’s drug, troriluzole, which is designed to help people with mild to
moderate Alzheimer’s.
The medication is based on another drug,
riluzole, the first medication approved by the U.S. Food and Drug
Administration to treat ALS more than 20 years ago.
A 2012 study found it extended ALS patients’
survival by two to three months.
Like riluzole, Biohaven’s troriluzole
influences the brain chemicals that nerve cells use to communicate with each
other. This helps protect against neurodegeneration — the loss or function of
nerve cells.
this is really nice to read..informative post is very good to read..thanks a lot!thank you for your interesting infomation. drug studies near me
ReplyDelete